Kancera AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KAN.ST research report →
Companywww.kancera.com
Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers.
- CEO
- Peter Selin
- IPO
- 2011
- Employees
- 5
- HQ
- Solna, SE
Price Chart
Valuation
- Market Cap
- $36.05M
- P/E
- -0.06
- P/S
- 0.00
- P/B
- 0.20
- EV/EBITDA
- 0.44
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -148.07%
- ROIC
- -316.06%
Growth & Income
- Revenue
- $14.00K · -98.65%
- Net Income
- $-44,566,000 · 31.32%
- EPS
- $-0.39 · 51.25%
- Op Income
- $-46,161,000
- FCF YoY
- -5.14%
Performance & Tape
- 52W High
- $2.25
- 52W Low
- $0.24
- 50D MA
- $1.01
- 200D MA
- $1.16
- Beta
- 0.92
- Avg Volume
- 662.16K
Get TickerSpark's AI analysis on KAN.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our KAN.ST Coverage
We haven't published any research on KAN.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KAN.ST Report →